Leprosy for NEET PG Dermatology: Cardinal Signs, NLEP 2025 PB/MB Classification and 3-Drug MDT, Spectrum, Reactions and ENL, SDR-PEP

Start Here

🎯 Exam priority: High (Dermatology and PSM). Expect: the three cardinal signs, PB vs MB under the 2025 Indian rules, the three-drug regimen now used for PB too, doses and durations, tuberculoid vs lepromatous features, ulnar claw hand and foot drop, type 1 vs type 2 reactions and their drugs, SDR-PEP for contacts, Grade 2 disability as an indicator, and NLEP milestones.

CBME mapping: DR 9.1–9.6. Programme details are also in PSM; M. leprae in Microbiology.

NLEP 2025 PB and MB classification and regimen; WHO cardinal signs; leprosy spectrum; reactions and programme

NLEP 2025 PB and MB classification and regimen; WHO cardinal signs; leprosy spectrum; reactions and programme. Drawn by TrackNation.

The Disease and Its Diagnosis

  • Chronic infection by the acid-fast Mycobacterium leprae (and M. lepromatosis) with a tropism for skin, peripheral nerves, upper respiratory mucosa and eyes. Spread by droplets from the nose and mouth of untreated patients during prolonged close contact — not by casual contact; only untreated lepromatous disease is meaningfully contagious. Incubation: a few months to 20 years. Armadillos are a zoonotic source in the Americas.

  • WHO cardinal signs (any one is diagnostic): (1) definite loss of sensation in a pale or reddish skin patch; (2) a thickened peripheral nerve with sensory loss or weakness of the muscles it supplies; (3) bacilli on a slit-skin smear.

  • Spectrum: tuberculoid — one or a few anaesthetic, hypopigmented macules with sharp raised borders and enlarged nerves (good cell-mediated immunity); lepromatous — widespread symmetric nodules and thickening, loss of eyebrows and eyelashes, gynaecomastia, nose, testis and kidney involvement (poor cell-mediated immunity); borderline — unstable, shifting towards either pole. Biopsy the advancing edge in tuberculoid and a nodule in lepromatous disease; PCR helps in early or atypical cases.

  • Nerve damage: ulnar → claw 4th and 5th fingers; common peroneal → foot drop; corneal insensitivity and iritis → scarring and blindness. Lepromatous disease may cause amyloidosis and infertility.

Classification and Treatment (NLEP 2025)

  • PB: 1–5 skin lesions, no nerve involvement, smear negative. MB: more than 5 lesions, or one or more nerves involved (including pure neuritis), or a positive smear.

  • From 1 April 2025 India uses the same 3-drug MDT (rifampicin, clofazimine, dapsone) for PB and MB, replacing the old 2-drug PB regimen: 6 months for PB, 12 months for MB. Patients already on treatment on 31 March 2025 finish their old regimen. Monthly doses are supervised; daily doses are self-administered. MDT is free in all public facilities.

NLEP regimen (from 1 April 2025)

Rifampicin

Clofazimine

Dapsone

Duration

Adult PB

600 mg monthly

300 mg monthly + 50 mg daily

100 mg daily

6 months

Adult MB

600 mg monthly

300 mg monthly + 50 mg daily

100 mg daily

12 months

Child 10–14 y

450 mg monthly

150 mg monthly + 50 mg alternate days

50 mg daily

PB 6 / MB 12 months

Child (younger)

10 mg/kg monthly

100 mg monthly + 50 mg twice weekly

2 mg/kg daily

PB 6 / MB 12 months

Reactions, Disability and the Programme

  • Type 1 (reversal) reaction: a spontaneous rise in cell-mediated immunity — inflamed existing lesions and neuritis — treated with prednisone 40–60 mg/day tapered to a low maintenance dose over months; cyclosporine if steroids fail.

  • Type 2 reaction — erythema nodosum leprosum (ENL): immune-complex vasculitis/panniculitis with crops of painful red nodules, fever, neuritis, lymphadenitis, orchitis, arthritis and glomerulonephritis; less common since clofazimine joined MDT. Mild — aspirin; significant — a week of prednisone; recurrent or severe — thalidomide (never in women who may become pregnant).

  • Prevention: contact screening with single-dose rifampicin post-exposure prophylaxis (SDR-PEP) for eligible contacts. DPMR: self-care training, dressings, micro-cellular rubber (MCR) footwear, reconstructive surgery at district hospitals or medical colleges with a welfare allowance.

  • NLEP: began as NLCP in 1955 (dapsone monotherapy); MDT era from the 1980s; leprosy made notifiable in 2025; National Strategic Plan 2023–27 aims to interrupt transmission at district level by 2027 — zero transmission, disability and discrimination. Grade 2 disability in new cases is the key indicator of late diagnosis.

Traps the Examiner Sets

  • Since April 2025, PB patients in India also get clofazimine — three drugs for 6 months.

  • Any nerve involvement makes a case MB.

  • Type 1 = cell-mediated (reversal); type 2 = immune complex (ENL) → thalidomide if recurrent.

  • Grade 2 disability among new cases signals delayed detection.

Memory Hooks & Shortcuts

Shortcuts to lock in this article's numbers and lists. Each one only re-packages facts proven above.

  • 🧠 Cardinal signs 'Patch, Nerve, Smear' — any one — diagnosis

  • 🧠 'Five or fewer and nerve-free = PB' — classification

  • 🧠 MDT 'R-C monthly, D-C daily; 6 for PB, 12 for MB' — regimen

  • 🧠 Reactions: 'Type 1 = Turn-around immunity; Type 2 = Two (immune complexes), thalidomide' — reactions

  • 🧠 'Ulnar claws, Peroneal drops' — nerve deformities

Rapid-Revision Cards

  • Organism

    M. leprae (± M. lepromatosis); skin and nerves.

  • Spread

    Nasal/oral droplets, prolonged contact.

  • Incubation

    Months to 20 years.

  • Cardinal signs

    Anaesthetic patch; thick nerve; smear +.

  • PB (2025)

    1–5 lesions, no nerve, smear −.

  • MB (2025)

    > 5 lesions or any nerve or smear +.

  • MDT 2025

    R + C + D for both PB and MB.

  • Duration

    PB 6 months; MB 12 months.

  • Monthly

    R 600 + C 300 (supervised).

  • Daily

    D 100 + C 50.

  • Child 10–14

    R 450, C 150 monthly; D 50 daily.

  • Tuberculoid

    Few, sharp, anaesthetic; good CMI.

  • Lepromatous

    Many nodules, madarosis, gynaecomastia.

  • Ulnar

    Claw 4th–5th fingers.

  • Peroneal

    Foot drop.

  • Type 1

    Rising CMI → prednisone.

  • Type 2 (ENL)

    Painful nodules, orchitis → thalidomide.

  • SDR-PEP

    Single-dose rifampicin for contacts.

  • Notifiable

    2025.

  • NSP goal

    District-level interruption by 2027.

  • G2D

    Indicator of late diagnosis.

Sources

Facts in this article were checked against these documents.

  • National Leprosy Eradication Programme (NLEP) — Directorate General of Health Services, MoHFW, 2025 (link)

  • Revised treatment regimen for PB and MB cases in India (D.O. letter, 6 March 2025) — Directorate General of Health Services, MoHFW, 2025

  • Leprosy fact sheet — World Health Organization, January 2026 (link)

  • MSD Manual Professional: Leprosy (Hansen Disease) — Merck & Co. (MSD Manuals), reviewed 2026 (link)

  • Competency Based Undergraduate Curriculum, Dermatology (DR 9) — National Medical Commission, 2024

Test Yourself: Practice Questions

Thirty questions in NEET PG style, most of them clinical vignettes.

Practice Questions (NEET PG pattern)

Original questions written in the style of the exam: +4 for a correct answer, −1 for a wrong one. Every answer was checked against the sources listed above. NEET PG papers are not published by NBEMS, so these are not past-paper questions.

Q1. Leprosy is mainly transmitted by

  • (a) mosquitoes

  • (b) droplets from the nose and mouth of untreated patients during close contact

  • (c) shaking hands

  • (d) contaminated water

Show answer

Answer: (b) — Not by casual contact.


Q2. The incubation period of leprosy ranges from

  • (a) a few months to 20 years

  • (b) 1–3 days

  • (c) exactly 6 months

  • (d) 1–2 weeks

Show answer

Answer: (a) — Very long.


Q3. Which is a WHO cardinal sign of leprosy?

  • (a) silvery scales

  • (b) definite loss of sensation in a pale or reddish skin patch

  • (c) fever with rash

  • (d) itchy annular plaque

Show answer

Answer: (b) — Any one of three signs is enough.


Q4. The other two cardinal signs are

  • (a) anaemia and splenomegaly

  • (b) fever and weight loss

  • (c) a thickened nerve with sensory loss or weakness, and bacilli on slit-skin smear

  • (d) lymphadenopathy and cough

Show answer

Answer: (c) — WHO.


Q5. Under the 2025 Indian classification, a patient with 3 anaesthetic patches, no nerve involvement and a negative smear is

  • (a) multibacillary

  • (b) paucibacillary

  • (c) indeterminate, no treatment

  • (d) pure neuritic

Show answer

Answer: (b) — 1–5 lesions, no nerve, smear negative.


Q6. A patient with 2 skin patches and one thickened ulnar nerve is classified as

  • (a) tuberculoid, no treatment

  • (b) multibacillary

  • (c) paucibacillary

  • (d) pure neuritic PB

Show answer

Answer: (b) — Any nerve involvement → MB.


Q7. From 1 April 2025, paucibacillary leprosy in India is treated with

  • (a) rifampicin and dapsone for 6 months

  • (b) dapsone alone for 2 years

  • (c) rifampicin, clofazimine and dapsone for 6 months

  • (d) the same drugs for 12 months

Show answer

Answer: (c) — 3-drug regimen replaces the 2-drug PB regimen.


Q8. The duration of MDT for adult multibacillary leprosy is

  • (a) 3 months

  • (b) 24 months

  • (c) 12 months

  • (d) 6 months

Show answer

Answer: (c) — PB 6 months.


Q9. The supervised monthly doses in adult MDT are

  • (a) rifampicin 450 mg only

  • (b) isoniazid 300 mg

  • (c) rifampicin 600 mg and clofazimine 300 mg

  • (d) dapsone 100 mg and clofazimine 50 mg

Show answer

Answer: (c) — Daily: dapsone 100 + clofazimine 50.


Q10. The adult daily self-administered doses in MDT are

  • (a) rifampicin 600 mg daily

  • (b) clofazimine 300 mg daily

  • (c) dapsone 100 mg and clofazimine 50 mg

  • (d) dapsone 50 mg alternate days

Show answer

Answer: (c) — Per NLEP table.


Q11. A 12-year-old with MB leprosy receives monthly rifampicin of

  • (a) 150 mg

  • (b) 600 mg

  • (c) 450 mg

  • (d) 10 mg/kg weekly

Show answer

Answer: (c) — Child 10–14: rifampicin 450, clofazimine 150 monthly.


Q12. A patient has one hypopigmented, numb macule with a sharp raised border and an enlarged nerve nearby; immunity to M. leprae is strong. The pole of the spectrum is

  • (a) lepromatous

  • (b) borderline lepromatous

  • (c) histoid

  • (d) tuberculoid

Show answer

Answer: (d) — Few lesions, good CMI.


Q13. Widespread symmetric nodules, loss of eyebrows and gynaecomastia indicate

  • (a) type 1 reaction

  • (b) lepromatous leprosy with poor cell-mediated immunity

  • (c) indeterminate leprosy

  • (d) tuberculoid leprosy

Show answer

Answer: (b) — Lepromatous pole.


Q14. Clawing of the ring and little fingers in leprosy results from involvement of the

  • (a) ulnar nerve

  • (b) median nerve

  • (c) radial nerve

  • (d) common peroneal nerve

Show answer

Answer: (a) — Peroneal → foot drop.


Q15. Foot drop in leprosy is due to damage of the

  • (a) sciatic nerve trunk

  • (b) femoral nerve

  • (c) common peroneal nerve

  • (d) tibial nerve

Show answer

Answer: (c) — Lateral popliteal.


Q16. Blindness in leprosy can follow

  • (a) retinal detachment only

  • (b) cataract from MDT

  • (c) optic neuritis only

  • (d) corneal insensitivity with scarring, or iritis

Show answer

Answer: (d) — Eye care is part of DPMR.


Q17. For skin biopsy in tuberculoid leprosy, the sample is taken from the

  • (a) centre of the lesion

  • (b) advancing edge of the lesion

  • (c) earlobe only

  • (d) normal skin

Show answer

Answer: (b) — Nodules or plaques in lepromatous.


Q18. Existing leprosy patches suddenly become red and swollen with painful nerves during treatment. This type 1 reaction is due to

  • (a) secondary infection

  • (b) immune complex deposition

  • (c) a spontaneous rise in cell-mediated immunity

  • (d) drug allergy to dapsone

Show answer

Answer: (c) — Reversal reaction.


Q19. The treatment of a significant type 1 reaction is

  • (a) prednisone 40–60 mg/day, tapered to a low maintenance dose

  • (b) thalidomide

  • (c) antibiotics only

  • (d) stop MDT

Show answer

Answer: (a) — Cyclosporine second line.


Q20. A patient with lepromatous leprosy develops crops of painful red nodules with fever, neuritis and orchitis. The diagnosis is

  • (a) dapsone syndrome

  • (b) relapse

  • (c) type 1 reaction

  • (d) erythema nodosum leprosum (type 2 reaction)

Show answer

Answer: (d) — Immune-complex mediated.


Q21. The drug of choice for recurrent or severe ENL is

  • (a) isoniazid

  • (b) thalidomide

  • (c) dapsone

  • (d) rifampicin

Show answer

Answer: (b) — Not in women who may become pregnant.


Q22. ENL has become less common since the addition to MDT of

  • (a) dapsone

  • (b) rifampicin

  • (c) clofazimine

  • (d) ofloxacin

Show answer

Answer: (c) — Clofazimine is anti-inflammatory as well.


Q23. Household contacts of a new leprosy case are offered

  • (a) single-dose rifampicin post-exposure prophylaxis after screening

  • (b) dapsone for 2 years

  • (c) nothing

  • (d) BCG revaccination only

Show answer

Answer: (a) — SDR-PEP.


Q24. Under DPMR, patients with insensitive feet are given

  • (a) steroid injections

  • (b) only analgesics

  • (c) micro-cellular rubber (MCR) footwear and self-care training

  • (d) amputation

Show answer

Answer: (c) — Disability prevention.


Q25. Leprosy was declared a notifiable disease in India in

  • (a) 2016

  • (b) 2005

  • (c) 1955

  • (d) 2025

Show answer

Answer: (d) — NLEP timeline.


Q26. The National Strategic Plan for leprosy aims to interrupt transmission at district level by

  • (a) 2047

  • (b) 2035

  • (c) 2027

  • (d) 2030

Show answer

Answer: (c) — WHO Global Leprosy Strategy runs to 2030.


Q27. Which NLEP indicator best reflects delayed diagnosis?

  • (a) Grade 2 disability among new cases

  • (b) number of MDT blister packs

  • (c) child sex ratio

  • (d) prevalence rate

Show answer

Answer: (a) — Visible deformity at diagnosis.


Q28. India's leprosy control programme began in 1955 using

  • (a) rifampicin alone

  • (b) MDT

  • (c) BCG

  • (d) dapsone monotherapy

Show answer

Answer: (d) — MDT came in the 1980s.


Q29. A patient treated for leprosy needs reconstructive surgery for a claw hand. Under NLEP this is done at

  • (a) district hospitals, medical colleges or leprosy institutes, with a welfare allowance

  • (b) it is not offered

  • (c) private clinics only

  • (d) PHC only

Show answer

Answer: (a) — Rs 12,000 allowance.


Q30. Which form of leprosy is contagious?

  • (a) patients on MDT

  • (b) tuberculoid on treatment

  • (c) all forms, highly

  • (d) only untreated lepromatous (multibacillary) disease, and not easily

Show answer

Answer: (d) — Patients become non-infectious quickly on MDT.

Active Recall

From memory: give the cardinal signs, the 2025 PB/MB definitions and the adult MDT regimen with durations, contrast tuberculoid and lepromatous leprosy, describe the nerve deformities, explain type 1 and type 2 reactions with treatment, and list NLEP prevention measures and goals.